NCT07608978招募中2 期
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
The First Affiliated Hospital with Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2026年6月1日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 35
- 试验地点
- 1
研究概览
简要总结
This is a prospective, open-label, single-arm, single-center, Phase II clinical study designed to evaluate the efficacy and safety of Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes.
After successful screening, enrolled patients will receive 6 treatment cycles (21 days per cycle). Disease response will be assessed by CT/PET-CT during treatment and after completion of induction. Patients who achieve CR/PR/SD will proceed to the maintenance phase; patients who do not achieve at least SD (i.e., fail to reach CR/PR/SD) during induction will discontinue the study. Patients with CR/PR/SD after induction will receive maintenance therapy with zanubrutinib plus tislelizumab until disease progression, unacceptable toxicity, or completion of 1 year of maintenance.
Efficacy and safety assessments will be performed per protocol. Tumor response will be assessed by site investigators according to the 2014 Lugano criteria, including determination of response status, date of response, and date of progression/relapse.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years at the time of signing informed consent. Histologically confirmed Diffuse Large B-Cell Lymphoma (DLBCL) with MCD/BN2/N1 molecular subtypes defined by LymphGen classification.
- •Previously untreated (treatment-naïve). International Prognostic Index (IPI) score of 2-
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or
- •Life expectancy ≥6 months. At least one measurable lesion in two dimensions, defined as a maximum diameter >1.5 cm by CT or MRI.
- •Left Ventricular Ejection Fraction (LVEF) ≥50% as assessed by echocardiogram (ECHO).
- •Adequate hematologic function (unless due to underlying disease, e.g., extensive bone marrow involvement, or splenomegaly secondary to splenic involvement deemed by the investigator to be caused by DLBCL; blood product transfusions are allowed), defined as follows:
- •Hemoglobin ≥9.0 g/dL within 7 days prior to first treatment, without packed RBC transfusion.
- •Absolute Neutrophil Count (ANC) ≥1.0 × 10⁹/L. Platelet count ≥75 × 10⁹/L. Female participants of childbearing potential: Must agree to abstain from heterosexual intercourse or use contraception, and agree not to donate ova.
- •Male participants: Must agree to abstain from heterosexual intercourse or use contraception, and agree not to donate sperm.
排除标准
- •Contraindication to any component of the Pola-ZRCHP regimen. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding onychomycosis) at screening, or any major infection occurring within 4 weeks prior to the first dose of study treatment (as judged by the investigator).
- •Suspected or latent tuberculosis (confirmed by positive IFNγ release assay). Currently pregnant or breastfeeding, or planning a pregnancy during the study period or within 12 months after the last dose.
- •History of confirmed Progressive Multifocal Leukoencephalopathy (PML). Current or history of Central Nervous System (CNS) lymphoma. Evidence of significant, uncontrolled concomitant disease that may affect compliance with the protocol or interpretation of results.
- •Severe or extensive cardiovascular disease, such as New York Heart Association (NYHA) Class III or IV, or objective assessment of Class C or D cardiac disease; myocardial infarction within the past 6 months; unstable arrhythmias; or unstable angina.
- •Clinically significant liver disease, including active viral hepatitis or other hepatitis, current alcohol abuse, or cirrhosis.
- •Any of the following abnormal laboratory values (unless these abnormalities are solely attributable to underlying lymphoma):
- •INR or PT >1.5 × Upper Limit of Normal (ULN) in the absence of therapeutic anticoagulation.
- •PTT or aPTT >1.5 × ULN in the absence of lupus anticoagulant. Serum AST and ALT ≥2.5 × ULN. Total bilirubin ≥1.5 × ULN. Estimated creatinine clearance <40 mL/min (using the Cockcroft-Gault formula). Positive HBV DNA test result. Positive Hepatitis C test result (Hepatitis C virus [HCV] antibody serology). Note:Patients with positive HCV antibody are eligible only if the PCR test for HCV RNA is negative.
- •Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that gives reasonable suspicion of a disease or condition that contraindicates the use of the investigational drug(s).
研究者
研究点 (1)
Loading locations...
相似试验
招募中
4 期
To evaluate effect of the polatuzumab vedotin in combination with four other drugs, rituximab (R), cyclophosphamide (C), doxorubicin (H), and prednisone (P) in Lymphoma that develops from mature B-cell of patientsCTRI/2025/04/085952Roche Products India Pvt Ltd48
招募中
1 期
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)Small Cell Lung CancerNCT07531095Amgen160
尚未招募
2 期
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II StudyHead and Neck Squamous Cell CarcinomaNCT07589049Sun Yat-sen University42
尚未招募
4 期
In this study we will compare the combined role of medical treatment and surgical treatment in the management of vitiligo .CTRI/2024/10/076098AIIMS JODHPUR56
尚未招募
1/2 期
A Study to Assess the Safety,tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of sacituzumab vedotin.CTRI/2026/01/100358Zydus Lifesciences Limited42